Q1 2025 EPS Estimates for Balchem Co. Reduced by Analyst (NASDAQ:BCPC)

Balchem Co. (NASDAQ:BCPC) – Equities researchers at Sidoti Csr lowered their Q1 2025 earnings per share (EPS) estimates for shares of Balchem in a research report issued on Wednesday, October 9th. Sidoti Csr analyst K. May now expects that the basic materials company will post earnings of $1.16 per share for the quarter, down from their prior forecast of $1.18. The consensus estimate for Balchem’s current full-year earnings is $3.96 per share. Sidoti Csr also issued estimates for Balchem’s Q2 2025 earnings at $1.18 EPS, Q3 2025 earnings at $1.21 EPS, Q4 2025 earnings at $1.20 EPS and FY2025 earnings at $4.75 EPS.

Balchem (NASDAQ:BCPC) last announced its quarterly earnings results on Friday, July 26th. The basic materials company reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.95 by $0.03. Balchem had a return on equity of 10.94% and a net margin of 12.52%. The company had revenue of $234.08 million for the quarter, compared to the consensus estimate of $241.26 million.

Other analysts have also issued research reports about the company. HC Wainwright lifted their price objective on Balchem from $170.00 to $185.00 and gave the stock a “buy” rating in a report on Wednesday, July 31st. StockNews.com cut shares of Balchem from a “buy” rating to a “hold” rating in a research note on Monday, July 29th.

Balchem Trading Up 1.2 %

NASDAQ BCPC opened at $172.21 on Friday. The stock’s fifty day moving average price is $170.67 and its 200-day moving average price is $161.04. Balchem has a 12 month low of $110.74 and a 12 month high of $186.03. The company has a current ratio of 2.83, a quick ratio of 1.79 and a debt-to-equity ratio of 0.26. The stock has a market cap of $5.59 billion, a P/E ratio of 47.97, a P/E/G ratio of 5.43 and a beta of 0.65.

Institutional Investors Weigh In On Balchem

Large investors have recently bought and sold shares of the company. Congress Asset Management Co. MA raised its stake in shares of Balchem by 6.4% in the 4th quarter. Congress Asset Management Co. MA now owns 239,657 shares of the basic materials company’s stock valued at $35,649,000 after acquiring an additional 14,354 shares during the period. Vanguard Group Inc. lifted its position in Balchem by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 3,791,512 shares of the basic materials company’s stock worth $563,987,000 after acquiring an additional 30,868 shares during the period. GAMMA Investing LLC increased its stake in Balchem by 18.0% in the 1st quarter. GAMMA Investing LLC now owns 473 shares of the basic materials company’s stock valued at $73,000 after buying an additional 72 shares during the period. Annex Advisory Services LLC increased its stake in shares of Balchem by 4.8% during the first quarter. Annex Advisory Services LLC now owns 3,967 shares of the basic materials company’s stock worth $615,000 after acquiring an additional 182 shares during the period. Finally, Cardinal Capital Management raised its stake in shares of Balchem by 12.6% during the 1st quarter. Cardinal Capital Management now owns 21,999 shares of the basic materials company’s stock worth $3,409,000 after buying an additional 2,460 shares in the last quarter. 87.91% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Balchem

In other news, SVP Gunsteren Job Leonard Van sold 7,750 shares of the stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $180.05, for a total value of $1,395,387.50. Following the sale, the senior vice president now owns 8,540 shares in the company, valued at $1,537,627. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.25% of the stock is currently owned by company insiders.

About Balchem

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.